“BD’s new plant in Zaragoza will produce drug delivery devices, primarily for pharmaceutical companies that supply the European market with drugs in PFS such as vaccines and other biologics,” said Eric Borin, worldwide president of BD Pharmaceutical Systems.
In December, the medical technology company and pioneer of the prefilled syringe (BFS), announced plans to invest around US$1.2bn over a four-year period to expand and upgrade manufacturing capacity and technology for PFS, as well as advancing drug delivery systems (ADDS) across its six global manufacturing locations. It mentioned then that spend would include the addition of a new site in Europe, with the announcement this week of the Spanish build confirmation of that intention.
Lourdes López, general director of BD in Spain and Portugal, said the company began a detailed site location search process at the end of last year. That resulted in Zaragoza, Aragon being selected because of the optimal conditions offered by the region, the synergies that could be produced with BD’s Fraga facility as well as “the results and excellent performance of the plants that currently exist in Spain.”
BD told us the Spanish facility will come on stream by 2024 at the latest.
Outlining the rationale for the build, it said that while the first COVID-19 vaccines are in vials, future waves could be in pre-filled syringes, for speed and ease of delivery.
“There’s also strong growth in pre-filled drug delivery business for flu vaccines and biologic therapies, particularly for arthritis/diabetes, in home self-injection. Some 80% of biologics are now delivered by self-injection – autoinjectors that use pre-filled syringes – rather than IV infusions in hospitals or clinics.”